Physician profile
Jonathan T Schaaf
NPI 1033401294
$1,507.94
in general payments reported to CMS, 2019-2025
31 companies · $16.12 in 2025
The $16.12 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $56.71 · 2021: $165 · 2022: $180 · 2023: $435 · 2024: $456 · 2025: $16.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $216.76 | 2021-2024 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $151.67 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.75 | 2019-2024 | Xifaxan |
| Insightec,INC | $105.24 | 2023-2024 | Exablate |
| Boston Scientific Corporation | $86.73 | 2022-2024 | Watchman Flx |
| Novo Nordisk INC | $85.22 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $69.82 | 2023 | Cologuard Collection Kit |
| Genentech USA, INC. | $53.83 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $50.12 | 2022-2024 | Uptravi, Opsumit |
| Abbott Laboratories | $49.90 | 2023 | Freestyle Libre 3, Amplatzer Amulet |
| Eisai INC. | $47.76 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $47.06 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.62 | 2022 | |
| Edwards Lifesciences Corporation | $42.16 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amgen INC. | $37.01 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $35.41 | 2019-2024 | Shingrix, Arexvy |
| Daiichi Sankyo INC. | $23.74 | 2024 | Injectafer |
| Teva Pharmaceuticals USA, INC. | $20.95 | 2023 | Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $20.45 | 2021 | |
| Indivior INC. | $18.86 | 2024 | Sublocade |
| Grt US Holding, INC. | $18.48 | 2022 | |
| Lilly USA, LLC | $18.08 | 2024 | Zepbound |
| Endo Pharmaceuticals INC. | $17.57 | 2019 | |
| Scpharmaceuticals INC. | $16.30 | 2024 | |
| Amarin Pharma, INC. | $15.68 | 2022 | |
| Philips North America LLC | $15.34 | 2024 | (Ck6) Holter |
| Shire North American Group INC | $14.71 | 2019 | |
| Watermark Medical, INC. | $13.59 | 2024 | |
| Allergan, INC. | $13.55 | 2020 | |
| Tactile Systems Technology INC | $12.77 | 2020 | |
| Currax Pharmaceuticals LLC | $11.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Schaaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.